Rexahn Pharmaceuticals Inc:企業のM&A・事業提携・投資動向

◆英語タイトル:Rexahn Pharmaceuticals Inc - Mergers & Acquisitions (M&A), Partnerships & Alliances and Investment Report
◆商品コード:DATA904C2026
◆発行会社(調査会社):MarketLine
◆発行日:2018年7月
◆ページ数:91
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール
◆対象地域:アメリカ
◆産業分野:製薬・医療
◆販売価格オプション(消費税別)
Single User(1名様閲覧用)USD350 ⇒換算¥51,800見積依頼/購入/質問フォーム
Site License(同一事業所内共有可)USD700 ⇒換算¥103,600見積依頼/購入/質問フォーム
Enterprisewide License(複数事業所内共有可)USD1,050 ⇒換算¥155,400見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はMarketLine社の日本における正規販売代理店です。同社発行の企業調査レポートに関するお問い合わせは弊社までお願い致します。
MarketLine社の概要はこちらでご確認いただけます。



【レポートの概要】

Rexahn Pharmaceuticals Inc – Mergers & Acquisitions (M&A), Partnerships & Alliances and Investment Report
Summary

Marketline’s Rexahn Pharmaceuticals Inc Mergers & Acquisitions (M&A), Partnerships & Alliances and Investments report includes business description, detailed reports on mergers and acquisitions (M&A), divestments, capital raisings, venture capital investments, ownership and partnership transactions undertaken by Rexahn Pharmaceuticals Inc since January2007.

Synopsis

Marketline’s Company Mergers & Acquisitions (M&A), Partnerships & Alliances and Investments reports offer a comprehensive breakdown of the organic and inorganic growth activity undertaken by an organization to sustain its competitive advantage.

Key Highlights

This report includes Rexahn Pharmaceuticals Inc’s contact information and business summary, tables, graphs, a list of partners and targets, a breakdown of financial and legal advisors, deal types, top deals by deal value, detailed deal reports, and descriptions and contact details of the partner, target, investor, and vendor firms, where disclosed.

The profile also includes detailed deal reports for all M&A, private equity, public offering, venture financing, partnership and divestment transactions undertaken by Rexahn Pharmaceuticals Inc. These deal reports contain information about target company financials, sources of financing, method of payment, deal values, and advisors for various parties, where disclosed.

Scope

- Provides intelligence on Rexahn Pharmaceuticals Inc’s M&A, strategic partnerships and alliances, capital raising and private equity transactions.
- Detailed reports of various financial transactions undertaken by Rexahn Pharmaceuticals Inc and its subsidiaries since 2007.
- Information about key financial and legal advisors for Rexahn Pharmaceuticals Inc’s financial deals transactions.
- Financial deals tables and charts covering deal value and volumes trend, deal types and geography-based deal activity.

Reasons to buy

- Access comprehensive financial deals data along with charts and graph covering M&A, private equity, and partnerships and alliances.
- Form an independent opinion about Rexahn Pharmaceuticals Inc’s growth strategies through the organic and inorganic activities undertaken since 2007.
- Track your competitors’ business structure and growth strategies.

【レポートの目次】

Table of Contents
COMPANY OVERVIEW AND KEY FACTS 2
TABLE OF CONTENTS 5
LIST OF TABLES 6
LIST OF FIGURES 6
TARGETS AND PARTNERS 7
PARTNERSHIP 8
Partnership – Overview 8
Partnership – Deal reports 9
CAPITAL RAISING 35
Capital Raising – Overview 35
Capital Raising – Deal reports 36
APPENDIX 81
Contact Us 81
About MarketLine Financial Deals Database 81
Deal Definition and Methodology 83
About MarketLine 90

List of Tables
Table 1: Rexahn Pharmaceuticals Inc partnership volume and value trend (2014-YTD2018)
Table 2: Rexahn Pharmaceuticals Inc partnership trend by key deal type (2014-YTD2018)
Table 3: Rexahn Pharmaceuticals Inc capital raising volume and value trend (2014-YTD2018)
Table 4: Rexahn Pharmaceuticals Inc capital raising by deal type (2014-YTD2018)

List of Figures
Figure 1: Rexahn Pharmaceuticals Inc partnership volume and value trend (2014-YTD2018)
Figure 2: Rexahn Pharmaceuticals Inc partnership trend by key deal type (2014-YTD2018)
Figure 3: Rexahn Pharmaceuticals Inc capital raising volume and value trend (2014-YTD2018)
Figure 4: Rexahn Pharmaceuticals Inc capital raising by deal type (2014-YTD2018)

★海外企業調査レポート[Rexahn Pharmaceuticals Inc:企業のM&A・事業提携・投資動向]についてメールでお問い合わせはこちら

■おすすめ企業レポート■
  • Lundin Gold Inc:企業の戦略・SWOT・財務情報
    Lundin Gold Inc - Strategy, SWOT and Corporate Finance Report Summary Lundin Gold Inc - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corpo …
  • MIS Implants Technologies Ltd-医療機器分野:企業M&A・提携分析
    Summary MIS Implants Technologies Ltd (MIS) is a medical device company that offers advanced products and solutions for dental implantology treatment. The company offers dental implants, tools and kits, superstructures, and solutions for oral restoration and health, among others. Its implants compri …
  • Cordis Corp-医療機器分野:企業M&A・提携分析
    Summary Cordis Corporation (Cordis), a subsidiary of a Cardinal Health Inc., develops and manufactures interventional vascular products in the area of cardiology as well as for use in endovascular surgery. The company’s cardiology portfolio comprises sheaths, diagnostic guidewires, diagnostic cathet …
  • East Japan Railway Co:戦略・SWOT・企業財務分析
    East Japan Railway Co - Strategy, SWOT and Corporate Finance Report Summary East Japan Railway Co - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerin …
  • Select Medical Holdings Corp (SEM):企業の財務・戦略的SWOT分析
    Summary Select Medical Holdings Corp (SMHC) is a healthcare service provider that offers outpatient rehabilitation services. The center provides long-term acute care services such as cardiac services, infectious disease treatment, medically complex treatment, neuro or post-trauma, pulmonary or venti …
  • SBS Transit Ltd.:戦略・SWOT・企業財務分析
    SBS Transit Ltd. - Strategy, SWOT and Corporate Finance Report Summary SBS Transit Ltd. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and cor …
  • Bechtel Corporation:企業の戦略的SWOT分析
    Bechtel Corporation - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products and se …
  • Companhia de Transmissao de Energia Eletrica Paulista (TRPL4):企業の財務・戦略的SWOT分析
    Summary Companhia de Transmissao de Energia Eletrica Paulista (CTEEP) a subsidiary of Interconexion Electrica SA ESP, is an electric utility service provider that produces and distributes electricity. The utility owns and operates power generation plants and transmission lines and supplies electrici …
  • Fluor Corporation (FLR)-エネルギー分野:企業M&A・提携分析
    Summary Fluor Corporation (Fluor) is a provider of engineering and construction services. The company's service portfolio includes design, engineering, procurement, fabrication, modularization, construction, commissioning and maintenance, and project management solutions. Fluor also offers other ser …
  • NBCUniversal Media LLC:企業のM&A・事業提携・投資動向
    NBCUniversal Media LLC - Mergers & Acquisitions (M&A), Partnerships & Alliances and Investment Report Summary Marketline's NBCUniversal Media LLC Mergers & Acquisitions (M&A), Partnerships & Alliances and Investments report includes business description, detailed reports on mergers and acquisitions …
  • Aslan Pharmaceuticals Pte Ltd (6497):製薬・医療:M&Aディール及び事業提携情報
    Summary Aslan Pharmaceuticals Pte Ltd (Aslan), a subsidiary of Aslan Pharmaceuticals Ltd, is a biotechnology company that offers immuno-oncology agents and targeted therapies. The company’s pipeline products comprise varlitinib, ASLAN002, ASLAN003 and ASLAN004. Its ASLAN002 is a small molecule inhib …
  • Pakistan Petroleum Limited (PPL)-石油・ガス分野:企業M&A・提携分析
    Summary Pakistan Petroleum Limited (PPL) is an upstream oil and gas company. It explores, develops and produces crude oil and natural gas resources. The company produces crude oil, natural gas, natural gas liquids, liquefied petroleum gas and barytes. It operates producing fields in Sui, Kandhkot, A …
  • GOME Electrical Appliances Holding Limited:企業の戦略・SWOT・財務情報
    GOME Electrical Appliances Holding Limited - Strategy, SWOT and Corporate Finance Report Summary GOME Electrical Appliances Holding Limited - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, …
  • Fortis Healthcare Ltd (FORTIS):製薬・医療:M&Aディール及び事業提携情報
    Summary Fortis Healthcare Ltd (Fortis) is an integrated healthcare provider that delivers healthcare services in the Pan Asia-Pacific region. The company’s services portfolio comprises diagnostics, primary care, day care and specialty hospitals. It owns, operates, and manages a chain of multi-specia …
  • NTN Corp (6472):企業の財務・戦略的SWOT分析
    NTN Corp (6472) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and the p …
  • Grupo Televisa S.A.B.:企業の戦略・SWOT・財務情報
    Grupo Televisa S.A.B. - Strategy, SWOT and Corporate Finance Report Summary Grupo Televisa S.A.B. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerin …
  • Innoviva Inc (INVA):企業の財務・戦略的SWOT分析
    Innoviva Inc (INVA) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and t …
  • OptiNose US Inc (OPTN):製薬・医療:M&Aディール及び事業提携情報
    Summary OptiNose US Inc (OptiNose) is a specialty pharmaceutical company that develops and delivers new pipeline drugs through intranasal deposition of medications. The company offers products such as XHANCE fluticasone propionate and ONZETRA sumatriptan nasal powder. Its products are used in the th …
  • DIAsource ImmunoAssays SA:企業の製品パイプライン分析2018
    Summary DIAsource ImmunoAssays SA (DIAsource), formerly BioSource Europe SA, a subsidiary of BioVendor - Laboratorni Medicina as, is a diagnostics company that develops, manufactures and markets clinical diagnostic products. The company’s products comprise immunoassays, antibodies, instruments and R …
  • Ingles Markets Inc:企業の戦略・SWOT・財務情報
    Ingles Markets Inc - Strategy, SWOT and Corporate Finance Report Summary Ingles Markets Inc - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and …

◆H&Iグローバルリサーチ株式会社のお客様(例)◆